Immunome Administers IM-1021 in First Patient of Phase 1 ROR1-ADC Trial

BOTHELL, WA, USA I March 10, 2025 – Immunome, Inc., a biotechnology company listed on Nasdaq as IMNM, is advancing its mission to develop pioneering cancer therapies with the announcement of the initial dosing in a Phase 1 clinical trial. This trial marks the first human testing of IM-1021, an antibody-drug conjugate (ADC) targeting ROR1, a receptor often implicated in cancerous growths.

Dr. Bob Lechleider, the Chief Medical Officer at Immunome, emphasized the potential of their ADCs to significantly aid cancer patients. He highlighted that the progression to dosing the first patient with IM-1021 is a critical step in evaluating the drug's safety and effectiveness, particularly in individuals suffering from B-cell lymphomas and various solid tumors, where treatment options remain limited.

IM-1021 represents a cutting-edge approach in targeted cancer therapy. This novel ADC integrates Immunome’s proprietary TOP1 inhibitor, known as HC74, showcasing the company’s commitment to innovation. The current Phase 1 trial is designed as an open-label, multicenter study. Its primary goals are to evaluate the safety and tolerability of IM-1021 while also investigating its pharmacokinetics and initial anti-tumor activity. The trial aims to involve patients who have advanced B-cell lymphomas or advanced solid tumors, offering hope for those with challenging cancer diagnoses.

Immunome stands at the forefront of oncology treatment development, focusing on therapies that could set new standards in targeted cancer care. The company’s pipeline is diverse, featuring several promising candidates. Among these is varegacestat, previously known as AL102, a gamma secretase inhibitor currently undergoing a Phase 3 trial targeting desmoid tumors. Alongside IM-1021, which is now in Phase 1, the pipeline includes IM-3050, a FAP-targeted radioligand. An Investigational New Drug (IND) application for IM-3050 is anticipated to be submitted in early 2025.

Furthermore, Immunome is exploring other preclinical ADCs, namely IM-1617, IM-1335, and IM-1340. These are designed to target undisclosed markers prevalent in multiple solid tumors, indicating the company’s tailored approach to various cancer types.

Immunome’s leadership team is composed of individuals who have significantly contributed to the development and commercialization of innovative cancer treatments, particularly ADCs. This expertise fuels the company’s ambition to deliver first-in-class and best-in-class therapies that meet critical patient needs.

Through its strategic focus on targeted therapies, Immunome aims to improve the therapeutic landscape for cancer patients. Its commitment to advancing these treatments highlights a dedication to enhancing patient outcomes and addressing areas that have previously seen little progress.

As the Phase 1 trial progresses, the biotechnology community and cancer patients alike await further developments from Immunome, hopeful for breakthroughs that could transform cancer care. The trial’s outcomes will shed light on the potential of IM-1021 as a viable treatment option in oncology, paving the way for future developments in targeted cancer therapies.